Study to Assess Adverse Events When Subcutaneous Risankizumab Injection is Given to Adult Participants With Psoriasis in Real World Setting

Conditions

• Psoriasis

Eligibility Criteria

Sex

ALL

Age

18 Years - N/A

Healthy Volunteers

Not accepted

Interventions

• Risankizumab — DRUG
  Subcutaneous Injection
• Comparator 1 — BIOLOGICAL
  Subcutaneous or Intravenous Injection
• Comparator 2 — DRUG
  Oral, Opthalmic, Subcutaneous or Intravenous Injection

Study Details

Study is not recruiting and using secondary data sources only

Key Dates

Start date

Jun 23, 2021

Status verified

Dec 2022

Primary completion

Mar 10, 2022

Completion

Mar 10, 2022

Study Design

Enrollment

0 participants (actual)

Arms

• Arm: Risankizumab
  Participants will receive risankizumab as prescribed by their physician.
• Arm: Comparator Group 1
  Participants will receive biologics other than interleukin (IL)-23 antagonists as prescribed by their physician.
• Arm: Comparator Group 2
  Participants will receive non-biologic systemic small molecules as prescribed by their physician.

Primary Outcome Measure

Incidence Rate of Participants With Major Adverse Cardiovascular Events (MACE) [ Time Frame: Up to approximately 10 years ]

Related Studies

• Stelara and Tremfya Pregnancy Exposure Registry OTIS Autoimmune Diseases in Pregnancy Project
  Recruiting · University of California, San Diego · La Jolla, California
• Regulation of Inflammatory Genes in Psoriasis
  Recruiting · University of Alabama at Birmingham · Birmingham, Alabama
• LTS of Siliq vs. Other Therapies Treating of Adults With Moderate-to-Severe Psoriasis
  Enrolling By Invitation · Bausch Health Americas, Inc. · Bridgewater, New Jersey
• An Open-Label, Pilot Study to Evaluate the Efficacy of Narrowband Ultraviolet-B Phototherapy Three Times Weekly for Twelve Weeks in Moderate-to-Severe Psoriasis Patients
  Recruiting · Psoriasis Treatment Center of Central New Jersey · East Windsor, New Jersey